Respiratory syncytial virus (RSV) is a common virus that causes respiratory infection. The virus infects lungs and respiratory passage. RSV infection is common among adults who experience symptoms like mild cold however in infants and older people the infection can be very serious. RSV is the most common cause of bronchiolitis and pneumonia among infants. RSV infection is limited to the respiratory tract. The virus inoculates in the lower respiratory tract and spreads into the respiratory system through cell to cell transfer in syncytia. RSV infection has very high incidence rate. According to the Centers for Disease Control and Prevention (CDC), almost all children get RSV infection by the age of 2 years. Moreover the Respiratory syncytial virus spreads very quickly through cough, sneeze and touching the infected surfaces which delivers the virus into the host body. The recovery period for RSV infection is around 1 to 2 weeks among infants, the virus still remains in the body and can spread easily to another person. Owing to high incidence rate, the market for pediatric syncytial virus infection is expected to witness robust growth over the forecast period.
Pediatric Respiratory Syncytial Virus Infection Market: Drivers and Restraints
Growing incidence of RSV among children is expected to increase demand for RSV infection treatment products. Rise in the birth rate is expected to propel demand for RSV treatment products over the forecast period. According to the United Nations, Department of Economic and Social Affairs, the global population is expected to reach 8.5 billion by 2030. This increase in the baby boomer population is expected to add to the patient pool of the RSP virus and thus in turn increase demand for RSV infection treatment over the forecast period. RSV infection can occur at any age however the infection rate among children varies as compared to adults. Among infants and children, nearly 25 out of every 40 children suffering from RSV infection, exhibit signs of bronchiolitis or pneumonia. Owing to severity of the infection the awareness among public regarding the RSV infection is growing which in turn is expected to boost demand for respiratory syncytial virus infection treatment. Increase in the risk of acquiring RSV among children is associated with the community settings like attending school, exposure to environmental pollutants etc. with changing social dynamic structure the incidence rate of RSV infection is expected to grow rapidly over the forecast period. However absence of definitive treatment, side effects and limited efficacy of the drugs available in the market and dependency in symptom based treatment in several cases is expected to hamper revenue growth of the pediatric respiratory syncytial virus infection market over the forecast period.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2345
Pediatric Respiratory Syncytial Virus Infection Market: Segmentation
- Alpha agonists
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
Pediatric Respiratory Syncytial Virus Infection Market: Overview
The global market for pediatric respiratory syncytial virus infection is expected to witness robust growth owing to increasing incidence rate of the RSV infection and growth in the birth rate.
Pediatric Respiratory Syncytial Virus Infection Market: Region – wise Outlook
Globally the pediatric respiratory syncytial virus infection market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East and Africa (MEA). Globally RSV is responsible for nearly 18% of the total child deaths. North America and Western Europe are expected to be the leading markets in the global pediatric respiratory syncytial virus infection market. High awareness and easy available diagnostic tests are expected to boost demand for RSV infection treatment products in these regions. Japan and APEJ are expected to follow next in terms of demand for the treatment of pediatric respiratory syncytial virus infection market. Eastern Europe, Latin America and MEA markets are also expected to witness above average growth over the forecast period. Absence of population based studies in developing countries is a major challenge in assessment of RSV related infections in these countries.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2345
Pediatric Respiratory Syncytial Virus Infection Market: Participants
Some players in the global pediatric syncytial virus infection market are Ablynx NV, Aridis Pharmaceuticals, Inc., Artificial Cell Technologies, Inc. is conducting studies for development of vaccine against RSV. The company’s vaccines is into pre – clinical development and preparing for IND filing to conduct phase 1 trials. Astellas Pharma Inc. entered into strategic partnership with ClearPath Development company for building a vaccine portfolio for Respiratory Syncytial Virus, AstraZeneca is conducting observational studies of Respiratory Syncytial Virus Hospitalizations among U.S. infants. Bavarian Nordic., a biotechnology company is building a antibody based treatment against RSV, which is currently into phase 2 clinical trials.